USE OF CAPSULE ENDOSCOPY TO EVALUATE THE EFFECTS OF MELOXICAM AND DICLOFENAC ON THE SMALL BOWEL MUCOSA IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE FIRST EXPERIENCE

Small bowel (SB) injury is a common complication from the use of nonsteroidal anti-inflammatory drugs (NSAIDs). According to clinical trials, selective cyclooxygenase-2 inhibitors are safer in this respect. Meloxicam belongs to selective NSAIDs; however, its effect on the SB has been inadequately in...

Full description

Saved in:
Bibliographic Details
Main Authors: A E Karateev, A G Bochkova, O A Rumyantseva, E Yu Tyukhova, E L Nasonov
Format: Article
Language:Russian
Published: IMA PRESS LLC 2011-08-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/342
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849243313814634496
author A E Karateev
A G Bochkova
O A Rumyantseva
E Yu Tyukhova
E L Nasonov
author_facet A E Karateev
A G Bochkova
O A Rumyantseva
E Yu Tyukhova
E L Nasonov
author_sort A E Karateev
collection DOAJ
description Small bowel (SB) injury is a common complication from the use of nonsteroidal anti-inflammatory drugs (NSAIDs). According to clinical trials, selective cyclooxygenase-2 inhibitors are safer in this respect. Meloxicam belongs to selective NSAIDs; however, its effect on the SB has been inadequately investigated. Objective: to compare the effects of meloxicam 15 mg/day and diclofenac 150 mg/day on the SB mucosa. Subjects and methods. A study group comprised 15 patients, including 6 men and 9 women (mean age 42.3+17.1 years), with ankylosing spondylarthritis (AS); 7 of them took meloxicam 15 mg/day for at least one month and 8 had diclofenac 100-150 mg/day. The SB was evaluated from capsule endocopy (CE) readings. Results. SB erosions (n = 3 to 20 or more) were found in 11 patients: 5 (71.3%) and 6 (75.0%) subjects taking meloxicam and diclofenac, respectively (p = 0.82). The average amount of erosions in those receiving meloxicam (6.2+4.7) was less than in those having diclofenac (9.4+7.3; p = 0.13). One patient taking diclofenac was suspected of having Crohn's disease shown by CE and then confirmed by colonoscopy. Conclusion. Meloxicam has demonstrated a less negative effect than diclofenac on SB, although this difference was statistically insignificant. Small and bowel pathology frequently occurs in patients with AS and may be associated not only with the negative effect of the drugs, but also with comorbid inflammatory bowel diseases. There is a need for further studies of the distal gastrointestinal tract and for those of the effect of NSAIDs on the SB.
format Article
id doaj-art-48951c5dd2e94939b81e5d5475a9d57b
institution Kabale University
issn 1995-4484
1995-4492
language Russian
publishDate 2011-08-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj-art-48951c5dd2e94939b81e5d5475a9d57b2025-08-20T03:59:31ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922011-08-01494313510.14412/1995-4484-2011-58282USE OF CAPSULE ENDOSCOPY TO EVALUATE THE EFFECTS OF MELOXICAM AND DICLOFENAC ON THE SMALL BOWEL MUCOSA IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE FIRST EXPERIENCEA E KarateevA G BochkovaO A RumyantsevaE Yu TyukhovaE L NasonovSmall bowel (SB) injury is a common complication from the use of nonsteroidal anti-inflammatory drugs (NSAIDs). According to clinical trials, selective cyclooxygenase-2 inhibitors are safer in this respect. Meloxicam belongs to selective NSAIDs; however, its effect on the SB has been inadequately investigated. Objective: to compare the effects of meloxicam 15 mg/day and diclofenac 150 mg/day on the SB mucosa. Subjects and methods. A study group comprised 15 patients, including 6 men and 9 women (mean age 42.3+17.1 years), with ankylosing spondylarthritis (AS); 7 of them took meloxicam 15 mg/day for at least one month and 8 had diclofenac 100-150 mg/day. The SB was evaluated from capsule endocopy (CE) readings. Results. SB erosions (n = 3 to 20 or more) were found in 11 patients: 5 (71.3%) and 6 (75.0%) subjects taking meloxicam and diclofenac, respectively (p = 0.82). The average amount of erosions in those receiving meloxicam (6.2+4.7) was less than in those having diclofenac (9.4+7.3; p = 0.13). One patient taking diclofenac was suspected of having Crohn's disease shown by CE and then confirmed by colonoscopy. Conclusion. Meloxicam has demonstrated a less negative effect than diclofenac on SB, although this difference was statistically insignificant. Small and bowel pathology frequently occurs in patients with AS and may be associated not only with the negative effect of the drugs, but also with comorbid inflammatory bowel diseases. There is a need for further studies of the distal gastrointestinal tract and for those of the effect of NSAIDs on the SB.https://rsp.mediar-press.net/rsp/article/view/342nonsteroidal anti-inflammatory drugscapsule endoscopyenteropathy
spellingShingle A E Karateev
A G Bochkova
O A Rumyantseva
E Yu Tyukhova
E L Nasonov
USE OF CAPSULE ENDOSCOPY TO EVALUATE THE EFFECTS OF MELOXICAM AND DICLOFENAC ON THE SMALL BOWEL MUCOSA IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE FIRST EXPERIENCE
Научно-практическая ревматология
nonsteroidal anti-inflammatory drugs
capsule endoscopy
enteropathy
title USE OF CAPSULE ENDOSCOPY TO EVALUATE THE EFFECTS OF MELOXICAM AND DICLOFENAC ON THE SMALL BOWEL MUCOSA IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE FIRST EXPERIENCE
title_full USE OF CAPSULE ENDOSCOPY TO EVALUATE THE EFFECTS OF MELOXICAM AND DICLOFENAC ON THE SMALL BOWEL MUCOSA IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE FIRST EXPERIENCE
title_fullStr USE OF CAPSULE ENDOSCOPY TO EVALUATE THE EFFECTS OF MELOXICAM AND DICLOFENAC ON THE SMALL BOWEL MUCOSA IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE FIRST EXPERIENCE
title_full_unstemmed USE OF CAPSULE ENDOSCOPY TO EVALUATE THE EFFECTS OF MELOXICAM AND DICLOFENAC ON THE SMALL BOWEL MUCOSA IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE FIRST EXPERIENCE
title_short USE OF CAPSULE ENDOSCOPY TO EVALUATE THE EFFECTS OF MELOXICAM AND DICLOFENAC ON THE SMALL BOWEL MUCOSA IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE FIRST EXPERIENCE
title_sort use of capsule endoscopy to evaluate the effects of meloxicam and diclofenac on the small bowel mucosa in patients with ankylosing spondylitis the first experience
topic nonsteroidal anti-inflammatory drugs
capsule endoscopy
enteropathy
url https://rsp.mediar-press.net/rsp/article/view/342
work_keys_str_mv AT aekarateev useofcapsuleendoscopytoevaluatetheeffectsofmeloxicamanddiclofenaconthesmallbowelmucosainpatientswithankylosingspondylitisthefirstexperience
AT agbochkova useofcapsuleendoscopytoevaluatetheeffectsofmeloxicamanddiclofenaconthesmallbowelmucosainpatientswithankylosingspondylitisthefirstexperience
AT oarumyantseva useofcapsuleendoscopytoevaluatetheeffectsofmeloxicamanddiclofenaconthesmallbowelmucosainpatientswithankylosingspondylitisthefirstexperience
AT eyutyukhova useofcapsuleendoscopytoevaluatetheeffectsofmeloxicamanddiclofenaconthesmallbowelmucosainpatientswithankylosingspondylitisthefirstexperience
AT elnasonov useofcapsuleendoscopytoevaluatetheeffectsofmeloxicamanddiclofenaconthesmallbowelmucosainpatientswithankylosingspondylitisthefirstexperience